ONCAlert | Upfront Therapy for mRCC
Videos  >  

Fedratinib and Ruxolitinib Improve Survival as Treatment of Myelofibrosis

Ruben Mesa, MD
Published Online:9:04 PM, Mon March 23, 2020

Ruben Mesa, MD, the director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the role of ruxolitinib (Jakafi) and fedratinib (Inrebic), first-generation JAK inhibitors, as treatment of patients with myelofibrosis (MF).

Both fedratinib and ruxolitinib are available as frontline agents for patients with MF. In this setting, both drugs have shown to have the ability to improve splenomegaly and symptoms in patients with intermediate- and advanced-risk disease, says Mesa.

Additionally, investigators believe there is a likelihood to improve and extend survival with these agents in patients with MF with less debilitation. In addition, there may also be long-term effects in patients with bone marrow histologic features, as well as more subtle evidence of disease modification.

<< View more resources and information regarding myeloproliferative neoplasms
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.